Mitoxantrone
Epigenetic Repression
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Epigenetic Repression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tucidinostat Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | CCC |
PREDNISONE TABLETS Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | CCC |
Azacitidine Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | CCC |
Same molecule, other indications
Mitoxantrone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →